BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 2969612)

  • 1. Inefficient binding of IgM immune complexes to erythrocyte C3b-C4b receptors (CR1) and weak incorporation of C3b-iC3b into the complexes.
    Kávai M; Rasmussen JM; Baatrup G; Zsindely A; Svehag SE
    Scand J Immunol; 1988 Jul; 28(1):123-8. PubMed ID: 2969612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The attachment of serum- and plasma-derived C3 to solid-phase immune aggregates and its relation to complement-mediated solubilization of immune complexes.
    Baatrup G; Svehag SE; Jensenius JC
    Scand J Immunol; 1986 Apr; 23(4):397-406. PubMed ID: 3486458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding and catabolism of aggregated immunoglobulins containing C3b by U937 cells.
    Mehta RL; Takahashi H; Rudick RA; Knutson DW
    J Immunol; 1986 Mar; 136(5):1765-71. PubMed ID: 2936811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of processing by erythrocyte C3b/C4b receptors (CR1) on binding of immune complexes to Raji cells and polymorphonuclear granulocytes.
    Rasmussen JM; Jepsen HH; Svehag SE
    Scand J Immunol; 1987 Oct; 26(4):437-44. PubMed ID: 2961050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum and plasma fibronectin binds to complement reacted immune complexes primarily via Clq.
    Baatrup G; Svehag SE
    Scand J Immunol; 1986 Nov; 24(5):583-90. PubMed ID: 3097811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zinc ions inhibit factor I-mediated release of CR1-bound immune complexes and degradation of cell-bound complement factors C3b and C4b.
    Jepsen HH; Teisner B; Svehag SE
    Scand J Immunol; 1990 Apr; 31(4):397-403. PubMed ID: 2139734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement fixation by solid phase immune complexes. Reduced capacity in SLE sera.
    Baatrup G; Jonsson H; Sjöholm A; Sturfelt G; Svehag SE
    J Clin Lab Immunol; 1988 Jun; 26(2):73-9. PubMed ID: 3264027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factor I co-factor activity of CR1 overcomes the protective effect of IgG on covalently bound C3b residues.
    Fries LF; Prince GM; Gaither TA; Frank MM
    J Immunol; 1985 Oct; 135(4):2673-9. PubMed ID: 3161945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Release of immune complexes bound to erythrocyte complement receptor (CR1), with particular reference to the role of factor I.
    Jepsen HH; Svehag SE; Jensenius JC; Sim RB
    Scand J Immunol; 1986 Aug; 24(2):205-13. PubMed ID: 2944215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune complex binding efficiency of erythrocyte complement receptor 1 (CR1).
    Madi N; Paccaud JP; Steiger G; Schifferli JA
    Clin Exp Immunol; 1991 Apr; 84(1):9-15. PubMed ID: 1826650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding of model immune complexes to erythrocyte CR1 facilitates immune complex uptake by U937 cells.
    Emlen W; Burdick G; Carl V; Lachmann PJ
    J Immunol; 1989 Jun; 142(12):4366-71. PubMed ID: 2524529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of complement-solubilized immune complexes with CR1 receptors on human erythrocytes. The binding reaction.
    Jepsen HH; Svehag SE; Jarlbaek L; Baatrup G
    Scand J Immunol; 1986 Jan; 23(1):65-73. PubMed ID: 2939551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unique role of the complement receptor CR1 in the degradation of C3b associated with immune complexes.
    Medof ME; Iida K; Mold C; Nussenzweig V
    J Exp Med; 1982 Dec; 156(6):1739-54. PubMed ID: 7175439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding and catabolism of aggregated immunoglobulins bearing C3b or iC3b by U937 cells.
    Daha MR; Gorter A; Leijh PJ; Klar N; van Es LA
    Immunology; 1988 Jul; 64(3):375-9. PubMed ID: 2970428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Processing of C3b-opsonized immune complexes bound to non-complement receptor 1 (CR1) sites on red cells: phagocytosis, transfer, and associations with CR1.
    Craig ML; Waitumbi JN; Taylor RP
    J Immunol; 2005 Mar; 174(5):3059-66. PubMed ID: 15728520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isotypic and clonal variations in the interactions between model monoclonal immune complexes and the human erythrocyte CR1 receptor.
    Yokoyama I; Waxman F
    Mol Immunol; 1992; 29(7-8):935-47. PubMed ID: 1386141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative analyses of C3b capture and immune adherence of IgM antibody/dsDNA immune complexes.
    Taylor RP; Wright EL; Pocanic F
    J Immunol; 1989 Dec; 143(11):3626-31. PubMed ID: 2584711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative analyses of the relationship between C3 consumption, C3b capture, and immune adherence of complement-fixing antibody/DNA immune complexes.
    Edberg JC; Tosic L; Wright EL; Sutherland WM; Taylor RP
    J Immunol; 1988 Dec; 141(12):4258-65. PubMed ID: 3198918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphorylation of C3 by a casein kinase released from activated human platelets increases opsonization of immune complexes and binding to complement receptor type 1.
    Nilsson-Ekdahl K; Nilsson B
    Eur J Immunol; 2001 Apr; 31(4):1047-54. PubMed ID: 11298329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutrophil Fc gamma and complement receptors involved in binding soluble IgG immune complexes and in specific granule release induced by soluble IgG immune complexes.
    Voice JK; Lachmann PJ
    Eur J Immunol; 1997 Oct; 27(10):2514-23. PubMed ID: 9368604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.